Shire to re-file ADHD drug this year
Shire is now gearing up to re-file its attention-deficit hyperactivity drug SHP 465 in the US by the end of this year, on the back of new data further backing its safety and efficacy.
Read More
Tag: SHP 465
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
